The crosstalk between metabolic reprogramming and epithelial-mesenchymal transition and their synergistic roles in distant metastasis in breast cancer

Liyan Yu,Yongni Chen,Yingyu Chen,Kangwei Luo
DOI: https://doi.org/10.1097/md.0000000000038462
IF: 1.6
2024-06-15
Medicine
Abstract:Breast cancer (BRCA), the most common malignant tumor in women worldwide, is the second leading cause of cancer-related deaths among women. Globally, an estimated 2.3 million new cases [ 1 ] and 685,000 deaths [ 2 ] occurred in 2020. In 2022, approximately 290,560 new cases and 43,780 deaths were reported in the United States alone. [ 3 ] It is now understood that breast cancer exhibits significant intra and inter-tumor heterogeneity. However, once distant metastasis occurs, the chances of long-term survival for patients decrease drastically. Metastatic breast cancer is rarely curable, and treatment generally focuses on palliative care. According to the American Cancer Society, stage IV patients have a 5-year relative survival rate of 26%, compared to nearly 100% for stage I patients. [ 2 ] Based on the presence or absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (ERBB2; formerly HER2) molecular markers, breast cancer can be classified into 3 main subtypes: hormone receptor-positive/ERBB2-negative (70% of patients), ERBB2-positive (15–20%), and triple-negative (lacking all 3 standard molecular markers; 15%). While early-stage breast cancer often has a favorable prognosis after comprehensive treatment (including surgery), the therapeutic outcomes for intermediate and late-stage breast cancer are limited. In this respect, triple-negative breast cancer has a median overall survival of about 1 year. [ 4 ] Therefore, assessing the risk of distant metastasis and recurrence of breast cancer is particularly important, which provide a basis for clinical decisions in treatments for breast cancer patients.
medicine, general & internal
What problem does this paper attempt to address?